A competitor’s readout rarely changes everything, and it rarely changes nothing. The task is to work out which parts of your plan depend on what was just reported.
Start with who was studied
Compare the population with yours: disease setting, line of therapy, biomarker selection and prior treatment. A strong result in a population you do not intend to treat is useful context, but it is not a result about your program.
Check the maturity of the evidence
Ask how long patients were followed, how many events have occurred and how the key endpoints were assessed. Early response data and immature time-to-event data support a different set of conclusions than a mature randomized comparison. FDA’s endpoint guidance is a helpful reminder of how different endpoints support different claims.
Be disciplined about cross-trial comparison
Placing two results side by side is tempting and often misleading. Differences in eligibility, assessment schedule, response criteria, supportive care and follow-up can account for apparent gaps. State what the comparison can show, and what would need a head-to-head or better-matched dataset.
Follow the consequences through your plan
Trace the readout to the parts of your program it touches: the comparator in your protocol, eligibility criteria, enrollment competition, endpoint choice, the position you intend to occupy and the evidence a partner or regulator will now expect.
Decide what to watch next
Some readouts call for action now; others for waiting on a data cut, a subgroup analysis or a regulatory decision. Name the specific event that would change your view.
Public reference points
Related service: Competitive intelligence.